Oncology Landing 2015 Content

Publication
Article

NOVEMBER 2015

Volume 29 • Number 11

featured article

Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma

Benjamin A. Weinberg, MD, Cinthya S. Yabar, MD, Jonathan R. Brody, PhD, and Michael J. Pishvaian, MD, PhD

This article reviews the current treatment paradigms for metastatic disease, focusing on ways to ameliorate symptoms and lengthen survival. We then summarize recent advances in our understanding of the molecular and cellular aspects of pancreatic cancer.

Read article

Related Links

About Us

Archives

Supplements

Subscribe

Advertising

Guide to Authors

Reprints / Permissions

Editors / Publishers

Contact Us

October 2015 Issue

Oncology Digital Edition

view Past Digital Editions

Editors-in-Chief:

Julie M. Vose, MD

Nancy E. Davidson, MD

Nora Janjan, MD, MPSA, MBA

William C. Wood, MD

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
4 experts are featured in this series.
4 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
7 experts are featured in this series.
2 KOLs are featured in this series.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
2 experts are featured in this series.
Related Content
No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors

Roman Fabbricatore
November 2nd 2025
Article

No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Ariana Pelosci
November 2nd 2025
Article

Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

Anne Chiang, MD
October 20th 2025
Podcast

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

Tim Cortese
November 1st 2025
Article

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.

AI may transform oncology with Scout, an innovative assistant enhancing clinical insights and treatment strategies for TP53-mutant MCL and multiple myeloma.

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights

Gina Mauro
November 1st 2025
Article